ES8405032A1 - Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina. - Google Patents
Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina.Info
- Publication number
- ES8405032A1 ES8405032A1 ES521362A ES521362A ES8405032A1 ES 8405032 A1 ES8405032 A1 ES 8405032A1 ES 521362 A ES521362 A ES 521362A ES 521362 A ES521362 A ES 521362A ES 8405032 A1 ES8405032 A1 ES 8405032A1
- Authority
- ES
- Spain
- Prior art keywords
- lankacidin
- inclusion compound
- group antibiotic
- antibiotic
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000003115 biocidal effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 2
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 208000001848 dysentery Diseases 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
PROCEDIMIENTO PARA LA OBTENCION DE COMPUESTOS DE INCLUSION DE ANTIBIOTICOS DEL GRUPO DE LA LANKACIDINA CON CICLODEXTRINA.CONSISTE EN DISOLVER CICLODEXTRINA, EN CONCENTRACION ENTRE 10-4 Y 10-1 MOLES/L, EN UN DISOLVENTE DE LA LANKACIDINA; AÑADIR LA CANTIDAD DESEADA DE ANTIBIOTICO DEL GRUPO DE LA LANKADICINA, AGITAR LA MEZCLA RESULTANTE Y, FILTRAR LOS POSIBLES MATERIALES NO DISUELTOS; Y AMASAR Y LIOFILIZAR LA DISOLUCION HASTA OBTENER UN MATERIAL SOLIDO.ESTOS COMPUESTOS TIENEN APLICACIONES EN FARMACOLOGIA POR SU ACTIVIDAD COMO AGENTES ANTIBACTERIANOS Y ANTITUMORALES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57061343A JPS58177949A (ja) | 1982-04-12 | 1982-04-12 | ランカシジン群抗生物質包接化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES521362A0 ES521362A0 (es) | 1984-05-16 |
ES8405032A1 true ES8405032A1 (es) | 1984-05-16 |
Family
ID=13168385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES521362A Expired ES8405032A1 (es) | 1982-04-12 | 1983-04-11 | Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina. |
Country Status (8)
Country | Link |
---|---|
US (1) | US4497803A (es) |
EP (1) | EP0091782B1 (es) |
JP (1) | JPS58177949A (es) |
CA (1) | CA1216581A (es) |
DE (1) | DE3372577D1 (es) |
DK (1) | DK158883A (es) |
ES (1) | ES8405032A1 (es) |
ZA (1) | ZA832471B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0094157B1 (en) * | 1982-04-30 | 1987-07-29 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its use |
HU196230B (en) * | 1983-12-29 | 1988-10-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing water-soluble forms of polyene antibiotics and pharmaceutics comprising such active ingredient and plant protective with antifungal effect |
US4616008A (en) * | 1984-05-02 | 1986-10-07 | Takeda Chemical Industries, Ltd. | Antibacterial solid composition for oral administration |
US4883785A (en) * | 1984-07-27 | 1989-11-28 | Chow Wing Sun | Complex of anti-fungal agent and cyclodextrin and method |
JPS61207380A (ja) * | 1985-03-11 | 1986-09-13 | Taiyo Yakuhin Kogyo Kk | モベンゾキサミンの経口製剤 |
US4914206A (en) * | 1985-10-06 | 1990-04-03 | Takeda Chemical Industries, Ltd. | Lankacidin derivatives and production thereof |
ES2058057T3 (es) * | 1985-12-05 | 1994-11-01 | Takeda Chemical Industries Ltd | Derivados de lancacidina y su produccion. |
US4885275A (en) * | 1987-10-15 | 1989-12-05 | Eli Lilly And Company | Vancomycin-HCL solutions and the lyophilization thereof |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
MY106598A (en) * | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5068227A (en) * | 1989-01-18 | 1991-11-26 | Cyclex, Inc. | Cyclodextrins as carriers |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
AT400674B (de) * | 1991-07-24 | 1996-02-26 | Biochemie Gmbh | Pharmazeutische pleuromutilin-zubereitung |
US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US20040014695A1 (en) * | 1992-06-19 | 2004-01-22 | Supergen, Inc. | Pharmaceutical formulation |
US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
DE69720283T2 (de) * | 1996-12-30 | 2004-01-29 | Univ Johns Hopkins Med | Bestimmung der krebsanfälligkeit eines organs oder gewebes durch bestimmung seiner zellprägung |
EP1332756A3 (en) * | 1996-12-30 | 2003-12-10 | The Johns Hopkins University School Of Medicine | Compositions and methods for restoring a normal pattern of imprinting to cells |
US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
MEP34508A (en) * | 2003-03-28 | 2011-02-10 | Ares Trading Sa | Cladribine formulations for improved oral and transmucosal delivery |
ME00249B (me) * | 2003-03-28 | 2011-05-10 | Ivax Corp | Oralne formulacije kladribina |
EP2272503B1 (en) | 2003-03-28 | 2013-03-20 | Ares Trading S.A. | Oral formulations of cladribine |
AU2005207786B2 (en) | 2004-01-29 | 2010-11-25 | Eisai R & D Management Co., Ltd | Method of stabilizing macrolide compound |
US20070010466A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
US20070009532A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |
US20070010487A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
US20070010485A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
US20070010486A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
US8845627B2 (en) | 2008-08-22 | 2014-09-30 | Boston Scientific Scimed, Inc. | Regulating pressure to lower temperature in a cryotherapy balloon catheter |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2959580A (en) * | 1956-10-17 | 1960-11-08 | Univ Minnesota | Formation of inclusion compounds |
JPS4810442B1 (es) * | 1968-10-26 | 1973-04-03 | ||
US3869443A (en) * | 1971-02-25 | 1975-03-04 | Sterling Drug Inc | N,N{40 -Heptamethylenebis(4-trifluoromethoxybenzamide)-{62 -cyclodextrin inclusion complex |
JPS5738569B2 (es) * | 1974-03-27 | 1982-08-16 | ||
HU176215B (en) * | 1978-01-27 | 1981-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1 |
JPS5724312A (en) * | 1980-07-18 | 1982-02-08 | Taisho Pharmaceut Co Ltd | Polyether antibiotic clathrate compound |
US4407795A (en) * | 1981-07-16 | 1983-10-04 | American Cyanamid Company | Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use |
-
1982
- 1982-04-12 JP JP57061343A patent/JPS58177949A/ja active Granted
-
1983
- 1983-04-05 CA CA000425214A patent/CA1216581A/en not_active Expired
- 1983-04-06 DE DE8383301941T patent/DE3372577D1/de not_active Expired
- 1983-04-06 US US06/482,553 patent/US4497803A/en not_active Expired - Fee Related
- 1983-04-06 EP EP83301941A patent/EP0091782B1/en not_active Expired
- 1983-04-08 ZA ZA832471A patent/ZA832471B/xx unknown
- 1983-04-11 ES ES521362A patent/ES8405032A1/es not_active Expired
- 1983-04-11 DK DK158883A patent/DK158883A/da not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US4497803A (en) | 1985-02-05 |
DK158883A (da) | 1983-10-13 |
JPH0336827B2 (es) | 1991-06-03 |
ES521362A0 (es) | 1984-05-16 |
CA1216581A (en) | 1987-01-13 |
DK158883D0 (da) | 1983-04-11 |
DE3372577D1 (en) | 1987-08-27 |
EP0091782A2 (en) | 1983-10-19 |
EP0091782B1 (en) | 1987-07-22 |
ZA832471B (en) | 1983-12-28 |
EP0091782A3 (en) | 1984-09-26 |
JPS58177949A (ja) | 1983-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES8405032A1 (es) | Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina. | |
ES455894A1 (es) | Procedimiento de secado de las soluciones que contienen aci-do borico. | |
SE8602404D0 (sv) | Ny formulering | |
ES8602032A1 (es) | Un procedimiento para la preparacion de nuevos derivados de daunorrubicina y doxorrubicina | |
AU562068B2 (en) | Agent for retarding polymerization of aziridine compounds | |
ES2041249T3 (es) | Preparaciones liquidas de 1,2-benzoisotiazolin-3-ona, su obtencion y empleo. | |
KR910003056A (ko) | 수성전분슬러리 접착제 | |
KR870000015A (ko) | 쑥차의 제조방법 | |
AU586169B2 (en) | Moulding material and process for its preparation | |
ES8507453A1 (es) | "mejoras en la preparacion de compuestos de adicion entre menadiona y tiamina". | |
ES448793A1 (es) | Procedimiento para la produccion de cerillas de friccion. | |
DE3360838D1 (en) | Composition for coating objects | |
JPS5214588A (en) | Brake fluid composition | |
ES479476A1 (es) | Procedimiento para la obtencion de celulosa. | |
ES462987A1 (es) | Un procedimiento para la obtencion de 2-furil-(3,4-dimetil-2-piridil)-carbinol. | |
SU1341767A1 (ru) | Способ получения йодинола | |
KR830006215A (ko) | 4-저급알킬-3-페녹시피리딘-1-옥사이드의 제조방법 | |
JPS51149348A (en) | Gel composition | |
ES438725A1 (es) | Un procedimiento de preparacion de derivados sustituidos del acido prostanoico. | |
JPS53130418A (en) | Stabilized prostaglandin composition | |
SE8305615L (sv) | Bindemedelskomposition | |
ZA893098B (en) | New acrylic derivative of urea | |
ES380386A1 (es) | Procedimiento para la preparacion de 5 - nitro-2-furfurili-den-amino - oxazolidinonas. | |
ES389332A1 (es) | Procedimiento para la preparacion de soluciones acuosas pu-ras de hexacianoferrato-(iii) potasico. | |
JPS53133300A (en) | Preparation of etherified polyoxyalkylene compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD1A | Patent lapsed |
Effective date: 19971201 |